Help SPARC-Europe Enhance NEN Cancer Care 🎗️
What is the NEN RADAR Survey?
Peptide receptor radionuclide therapy (PRRT), also known as radioligand therapy (RLT), can be a life-saving treatment for neuroendocrine neoplasm (NEN) cancer patients. However, many patients and healthcare professionals face significant challenges in accessing and understanding this treatment.
SPARC-Europe has launched the NEN Radioligand Awareness Research (NEN RADAR) to explore these challenges across Europe. The survey findings will inform evidence-based policy recommendations aimed at improving awareness, access, and availability of PRRT.
Who should participate?
We invite NEN cancer patients and healthcare professionals involved in their care to participate in this important survey.
Do you know someone who fits this description? Please share the survey with them and help spread the word.
Make a difference in the future of NEN cancer care! Click your relevant below to take the survey now.
🏥 Patient
SPARC-Europe would like to express its sincere appreciation to our NEN RADAR working group that has as its members prof. Dr. Ken Herrmann, prof. Dr. Philippe Ruszniewski, and Dr. Dirk van Genechten and was led by SPARC-Europe members prof. Dr. Nicola Fazio and Mark McDonnell. Additionally, the team would like to thank Dr. Robbe Saesen for his invaluable support in revising and reviewing the survey.
For any questions regarding the survey’s questions, objectives, or progress, feel free to contact us at secretariat@sparc-europe.com.